Company Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis.
In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation.
The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Feb 3, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 163 |
| CEO | Raymond Stevens |
Contact Details
Address: 601 Gateway Boulevard, Suite 900 South San Francisco, California 94080 United States | |
| Phone | 650 457 1978 |
| Website | structuretx.com |
Stock Details
| Ticker Symbol | GPCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001888886 |
| CUSIP Number | 86366E106 |
| ISIN Number | US86366E1064 |
| Employer ID | 98-1480821 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raymond C. Stevens Ph.D. | Chief Executive Officer and Director |
| Jun S. Yoon | Co- Founder, Chief Financial Officer and Secretary |
| Dr. Yingli Ma Ph.D. | Chief Technology Officer |
| Dr. Xichen Lin Ph.D. | Chief Scientific Officer |
| Tony Peng | Senior Vice President of Legal |
| Bob Gatmaitan | Senior Vice President of People |
| Dr. Hui Lei Ph.D. | Senior Vice President of Chemistry |
| Dr. Fang Zhang Ph.D. | Executive Vice President and Head of Biology |
| Lani Ibarra | Senior Vice President of Clinical Development Operations |
| Dr. Xinglong Jiang Ph.D. | Senior Vice President of Preclinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | SCHEDULE 13G | Filing |
| Dec 17, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |